Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). (Q42787157)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2010

Language	Label	Description	Also known as
English	Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).	scientific article published on September 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

quality of life

1 reference

based on heuristic

inferred from title

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

Bruno Spire

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Jean-Michel Molina

9

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

author name string

Thomas Boulet

1

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Juliette Pavie

2

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Isabelle Charreau

3

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Joséphine Braun

4

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Jacques Reynes

5

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Philippe Morlat

6

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Lionel Piroth

7

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Jean-Pierre Aboulker

10

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Easier-Anrs 138 Study Group

11

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

283-293

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV)

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Two approaches to measuring quality of life in the HIV/AIDS population: HAT-QoL and MOS-HIV.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Construct validities of the Quality of Well-Being Scale and the MOS-HIV-34 Health Survey for HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Reliability and Validity of Physical and Mental Health Summary Scores from the Medical Outcomes Study HIV Health Survey

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Defining clinically meaningful change in health-related quality of life.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Clinical significance of patient-reported questionnaire data: another step toward consensus.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Handling missing quality of life data in HIV clinical trials: what is practical?

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Incomplete quality of life data in randomized trials: missing forms

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Application of random effects models and other methods to the analysis of multidimensional quality of life data in an AIDS clinical trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

No adjustments are needed for multiple comparisons

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group

1 reference

https://api.crossref.org/works/10.1310%2FHCT1105-283

21 January 2018

Identifiers

10.1310/HCT1105-283

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42787157&oldid=1696769226"